Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Rises By 34.6%

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a significant increase in short interest in December. As of December 31st, there was short interest totaling 424,089 shares, an increase of 34.6% from the December 15th total of 315,078 shares. Based on an average daily volume of 125,839 shares, the days-to-cover ratio is currently 3.4 days. Currently, 1.3% of the company’s stock are short sold. Currently, 1.3% of the company’s stock are short sold. Based on an average daily volume of 125,839 shares, the days-to-cover ratio is currently 3.4 days.

Institutional Trading of Oramed Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in shares of Oramed Pharmaceuticals by 4.4% in the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 6,261 shares during the period. BML Capital Management LLC increased its stake in Oramed Pharmaceuticals by 2.7% in the 3rd quarter. BML Capital Management LLC now owns 3,167,231 shares of the biotechnology company’s stock valued at $8,361,000 after buying an additional 83,978 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Oramed Pharmaceuticals by 36.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,000 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 17,510 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Trading Down 0.3%

Shares of Oramed Pharmaceuticals stock traded down $0.01 during trading on Monday, reaching $3.68. The company’s stock had a trading volume of 319,878 shares, compared to its average volume of 253,934. The company has a 50-day moving average price of $2.90 and a two-hundred day moving average price of $2.48. Oramed Pharmaceuticals has a fifty-two week low of $1.82 and a fifty-two week high of $3.71. The firm has a market cap of $146.46 million, a PE ratio of 2.92 and a beta of 1.19.

Oramed Pharmaceuticals Dividend Announcement

The firm also recently announced a dividend, which will be paid on Monday, January 26th. Stockholders of record on Friday, January 16th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Friday, January 16th.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ORMP shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Oramed Pharmaceuticals to a “hold” rating in a research note on Saturday, November 1st. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Oramed Pharmaceuticals presently has a consensus rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.